EPAS1 and sarcoma: Given that HIF-2α expression opposes STS tumourigenesis, we sought a class of compounds that could induce re-expression of HIF-2α in sarcoma cells, and found that the FDA-approved HDACi SAHA (Vorinostat) reactivates EPAS1 expression in STS cells, inhibiting sarcoma progression (Fig. 6h).